What is Glaxosmithkline Pharmaceuticals Ltd (GLAXO) share price return in the past 10 years?

Glaxosmithkline Pharmaceuticals Ltd share price has appreciated 2.3% annually (CAGR) over the past ten years.

What is the share price of Glaxosmithkline Pharmaceuticals Ltd (GLAXO)?

Company share prices are keep on changing according to the market conditions. The current trading price of Glaxosmithkline Pharmaceuticals Ltd (GLAXO) on 09-Jun-2026 12:06:00 at 12:06 is 2199.90.

What is the P/E ratio of Glaxosmithkline Pharmaceuticals?

The latest standalone P/E ratio of Glaxosmithkline Pharmaceuticals as of 09-Jun-2026 is 36.56.

What is the P/B ratio of Glaxosmithkline Pharmaceuticals Ltd (GLAXO)?

The latest standalone P/B ratio of Glaxosmithkline Pharmaceuticals Ltd (GLAXO) as of 09-Jun-2026 is 16.39.

What is the 52-week high and low of Glaxosmithkline Pharmaceuticals Ltd (GLAXO)?

The 52-week high of Glaxosmithkline Pharmaceuticals Ltd (GLAXO) is Rs. 3500.00 and the 52-week low is Rs. 2155.00.

Glaxosmithkline Pharmaceuticals Ltd (GLAXO) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Glaxosmithkline Pharmaceuticals Ltd (GLAXO)
Brand: Glaxosmithkline Pharmaceuticals

Key Metrics

Valuation Multiples

Market Cap

₹36,990 Cr.

Current Price

₹2,199.9

52-Week Low / High

₹2,155 / 3,500

TTM EPS

₹61.2

TTM Sales

₹3,822 Cr.

Book Value per Share

₹134.8

P/E Ratio

35.71

Lower than its 5-year historical median

Industry PE

46.6

Price to Book (P/B)

16.20

Lower than its 5-year historical median

Price to Sales (P/S)

9.68

Lower than its 5-year historical median

EV/EBITDA

24.47

Lower than its 5-year historical median

Dividend Yield

2.50%

Profitability Efficiency

Return on Equity (ROE)

48.76%

Outperforms industry median

Return on Capital Employed (ROCE)

66.79%

Outperforms industry median

Return on Assets (ROA)

25.40%

Operating Profit Margin

34.4%

Net Profit Margin

27.11%

Gross Profit Margin

34.4%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Slowing versus 3-year growth rate

1.93%

Operating Profit Growth (1 Year)

Slowing versus 3-year growth rate

11.2%

Net Profit Growth (1 Year)

Slowing versus 3-year growth rate

11.69%

Asset Quality

Promoter Holding

75.00%

Pledged shares (%) of Promoter's holding (%)

0.00%

Reserves

₹2,114 Cr.

Equity

₹169.4 Cr.

Face Value

₹10

All Time Low / High

₹20.31 / 3515.95

Glaxosmithkline Pharmaceuticals stock performance

Key Ratios

Check Before You Invest

Quality

Locked

Valuation

Locked

Price Trend

Locked

Q.1 Is Glaxosmithkline Pharmaceuticals Ltd a good quality company?

Glaxosmithkline Pharmaceuticals Ltd is a good quality company, based on a consistently good multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

How does Glaxosmithkline Pharmaceuticals Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Glaxosmithkline Pharmaceuticals Ltd vs industry peers?

Glaxosmithkline Pharmaceuticals Ltd revenue CAGR is 3.06%, compared to the industry median CAGR of 9.13%, indicating slower growth and losing its market share.

Q.1 Promoter shareholding and pledge status of Glaxosmithkline Pharmaceuticals Ltd?

Promoters hold 75.00% of the Glaxosmithkline Pharmaceuticals Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Stock return of Glaxosmithkline Pharmaceuticals Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of 3.2% based on the current price.

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26	TTM
ROCE % ⓘ	24.4%	26.6%	32.5%	15.8%	27.7%	37.7%	38.1%	46.5%	67.6%	66.8%	-
Value Creation Index ⓘ	1.2	1.4	1.9	0.4	1.5	2.4	2.4	3.1	5.0	4.9	-
Growth Parameters ⓘ
Sales ⓘ	2,908	2,871	3,128	3,224	2,926	3,278	3,252	3,454	3,749	3,822	3,822
Sales YoY Gr.	-	-1.3%	8.9%	3.1%	-9.3%	12.1%	-0.8%	6.2%	8.6%	1.9%	-
Adj EPS ⓘ	18	20.3	25.2	12.4	25.5	21.4	35.1	38.7	51.8	57.2	61.2
YoY Gr.	-	13.3%	24.1%	-50.8%	105.6%	-16.3%	64.2%	10.4%	33.9%	10.4%	-
BVPS (₹) ⓘ	118.5	121.4	126.3	107.5	87.3	157.2	102.9	105.5	116.1	134.8	134.8
Adj Net Profit ⓘ	304	344	427	210	432	362	594	656	878	969	1,036
Cash Flow from Ops. ⓘ	234	473	409	491	578	811	484	582	1,290	903	-
Debt/CF from Ops. ⓘ	0	0	0	0	0	0	0	0	0	0	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	3.1%	5.5%	5.5%	1.9%
Adj EPS ⓘ	13.8%	17.5%	17.7%	10.4%
BVPSⓘ	1.4%	9.1%	9.4%	16.1%
Share Price	2.3%	8.2%	17.1%	-35.2%

Key Financial Parameters ⓘ

	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26	TTM
Return on Equity % ⓘ	14.5	17	20.4	10.6	26.2	17.5	27	37.3	47.1	46	45.4
Op. Profit Mgn % ⓘ	14.4	17.9	19.4	20.8	20.5	23.4	25	26.3	31.5	34.4	34.3
Net Profit Mgn % ⓘ	10.5	12	13.7	6.5	14.8	11	18.3	19	23.4	25.4	27.1
Debt to Equity ⓘ	0	0	0	0	0	0	0	0	0	0	0
Working Cap Days ⓘ	573	599	600	340	136	131	127	114	104	97	150
Cash Conv. Cycle ⓘ	24	9	-0	7	13	-4	-13	-12	-37	-34	71

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26
Sales	2,908	2,871	3,128	3,224	2,926	3,278	3,252	3,454	3,749	3,822
Operating Expenses ⓘ +	2,489	2,366	2,527	2,567	2,327	2,516	2,447	2,545	2,572	2,512
Manufacturing Costs	136	137	143	141	137	148	129	143	144	132
Material Costs	1,398	1,241	1,358	1,308	1,257	1,356	1,285	1,335	1,391	1,351
Employee Cost	483	523	537	629	616	610	595	624	580	607
Other Costs ⓘ	473	464	489	489	318	402	439	443	457	422
Operating Profit ⓘ	419	506	601	657	598	762	804	909	1,177	1,309
Operating Profit Margin (%)	14.4%	17.6%	19.2%	20.4%	20.4%	23.2%	24.7%	26.3%	31.4%	34.3%
Other Income ⓘ +	73	55	102	79	111	76	101	123	146	145
Exceptional Items ⓘ	46	18	29	-341	-173	12	-1	-144	5	21
Interest ⓘ	0	0	1	6	4	2	2	2	1	3
Depreciation ⓘ	26	38	49	83	79	68	66	70	67	66
Profit Before Tax ⓘ	511	540	683	306	454	779	836	816	1,260	1,406
Tax ⓘ	174	189	237	213	167	398	229	226	332	370
Profit After Tax	337	351	445	93	287	381	608	590	928	1,036
PAT Margin (%)	11.6%	12.2%	14.2%	2.9%	9.8%	11.6%	18.7%	17.1%	24.7%	27.1%
Adjusted EPS (₹)	19.9	20.7	26.3	5.5	21.1	100.0	36.1	34.8	54.8	61.2
Dividend Payout Ratio (%)	75.50%	84.50%	76.10%	727%	141.90%	90%	88.80%	91.90%	98.60%	93.20%

Valuation of Glaxosmithkline Phar - Consolidated

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26
Equity and Liabilities
Shareholders Fund +	2,007	2,057	2,140	1,821	1,478	2,663	1,743	1,787	1,966	2,283
Share Capital ⓘ	85	85	169	169	169	169	169	169	169	169
Reserves ⓘ	1,922	1,973	1,970	1,651	1,309	2,494	1,574	1,617	1,797	2,114
Debt +	1	1	0	0	0	0	0	0	0	0
Long Term Debt	1	1	0	0	0	0	0	0	0	0
Short Term Debt	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	279	506	406	357	466	579	428	625	708	570
Others Liabilities ⓘ	4,301	5,075	5,258	845	1,067	1,278	1,022	998	1,293	1,337
Total Liabilities ⓘ	6,588	7,639	7,804	3,023	3,012	4,520	3,193	3,410	3,967	4,190
Fixed Assets
Net Fixed Assets ⓘ +	253	323	430	757	386	329	329	320	283	280
Gross Block	299	406	559	1,452	601	592	634	663	667	716
Accumulated Depreciation	46	83	129	696	215	262	305	343	384	436
CWIP ⓘ	605	923	1,003	120	13	31	20	14	14	33
Investments ⓘ	0	0	0	0	0	366	518	813	1,118	1,392
Inventories	426	500	486	483	547	535	460	525	482	458
Trade Receivables	171	147	120	100	216	205	192	222	293	273
Cash Equivalents ⓘ	900	1,296	1,171	1,083	1,158	2,485	1,156	1,063	1,404	1,391
Others Assets ⓘ	4,233	4,449	4,593	480	692	570	517	452	374	364
Total Assets ⓘ	6,588	7,639	7,804	3,023	3,012	4,520	3,193	3,410	3,967	4,190

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26
Cash Flow From Operating Activity ⓘ +	234	473	409	490	578	811	484	582	1,290	903
PBT ⓘ	465	522	654	647	723	2,476	841	960	1,255	1,385
Adjustment ⓘ	-46	-12	-31	13	-26	-1,636	-40	-45	-68	-65
Changes in Working Capital ⓘ	-27	165	-4	44	46	120	-46	61	185	-98
Tax Paid ⓘ	-161	-202	-194	-180	-147	-112	-265	-254	-82	-319
Cash Flow From Investing Activity ⓘ +	301	-104	-153	-57	418	-406	808	9	-46	397
Capex	-258	-385	-243	-155	-42	1,232	-43	-28	-22	-54
Net Investments	472	-335	20	92	225	-1,812	956	-144	-144	317
Others ⓘ	87	616	70	6	235	175	-106	181	121	134
Cash Flow From Financing Activity ⓘ +	-511	-307	-358	-428	-696	-524	-1,543	-561	-769	-737
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	-1	-1	0	0	0	-0	0	0	0	0
Interest Paid ⓘ	-0	-0	-1	-4	-4	-2	-1	-2	-1	-3
Dividend Paid ⓘ	-424	-254	-296	-339	-677	-507	-1,525	-542	-749	-714
Others ⓘ	-86	-52	-61	-85	-15	-16	-17	-18	-19	-20
Net Cash Flow ⓘ	24	62	-102	6	300	-119	-251	29	475	563

Financial Ratio

PARTICULARS	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26
Ratios
ROE (%)	16.08	17.26	21.22	4.71	17.42	18.39	27.58	33.43	49.43	48.76
ROCE (%)	24.39	26.56	32.54	15.76	27.74	37.72	38.06	46.49	67.64	66.79
Asset Turnover Ratio	0.46	0.42	0.41	0.62	1.04	0.95	0.93	1.15	1.12	1.04
PAT to CFO Conversion(x)	0.69	1.35	0.92	5.27	2.01	2.13	0.8	0.99	1.39	0.87
Working Capital Days
Receivable Days	18.10	19.20	15.60	12	18.40	21.40	20.30	20	22.80	24.50
Inventory Days	57.90	56	57.60	52.60	60.10	54.90	50.90	47.50	44.60	40.60
Payable Days	79.20	115.40	122.50	106.50	119.50	140.70	143.10	144	175	172.70

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Glaxosmithkline Pharmaceuticals Ltd FAQs

The current trading price of Glaxosmithkline Phar on 09-Jun-2026 12:06 is ₹2,199.9.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 08-Jun-2026 the market cap of Glaxosmithkline Phar stood at ₹36,989.8 Cr

The latest P/E ratio of Glaxosmithkline Phar as of 08-Jun-2026 is 36.56.

The latest P/B ratio of Glaxosmithkline Phar as of 08-Jun-2026 is 16.39.

The 52-week high of Glaxosmithkline Phar is ₹3,500 and the 52-week low is ₹2,155.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Glaxosmithkline Phar is ₹3,790 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Glaxosmithkline Pharmaceuticals Ltd is a good quality company.

The key valuation ratios of Glaxosmithkline Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Glaxosmithkline Pharmaceuticals Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

About Glaxosmithkline Pharmaceuticals Ltd

GlaxoSmithKline (GSK) Pharmaceuticals, a subsidiary of UK-based GSK plc, is a leading global biopharma company bringing together science, technology and talent to deliver impact and get ahead of disease together worldwide. For decades, it has been an important proponent of the ‘Make in India’ vision, delivering pioneering breakthroughs in medicines and vaccines that have prevented diseases and improved the quality of life for millions in the country.

Its diverse product portfolio spans general medicines, specialty medicines and vaccines, addressing a broad spectrum of healthcare needs. From anti-infectives, pain management and dermatological products to advanced therapies in respiratory, to vaccines for adults and children, it harnesses scientific innovation and data-driven technologies to prevent and treat diseases effectively.

Business area of the company

The company is engaged in research, manufacture and making available a broad range of medicines and vaccines that benefit people. The company’s pharmaceuticals business has a broad portfolio of innovative and established medicines with commercial leadership in anti-infectives and dermatology. Its R&D approach focuses on science related to the immune system, use of genetics and advanced technologies. Meanwhile, its vaccines business has a broad portfolio and innovative pipeline of vaccines to protect people of all ages. The company is the leaders in India in the private segment.

Products of the company

Anti-Infectives
Pain Management
Hormones
Respiratory
Dermatologicals
Vitamins, Minerals, Nutritional products
Vaccines

Awards and recognitions

2017:

Pharma & Medical Devices Summit & Excellence Awards 2017
GSK India wins the Gold Award at the TISS - CLO Summit
GSK India won the 'Gold award' in the Sales Enablement Category at the Tata Institute of Social Sciences (TISS) - CLO Summit in Mumbai.

2018:

GSK ranked among the 50 best companies in India as per People Capital Index (PCI). GSK was conferred this recognition at the HR Leadership Summit 2018.
GSK won the OPPI Salesforce Excellence Award 2018. The award recognises its efforts in launching and scaling an innovative, mobile based platform for sales readiness.
Tbact bags the Silver award for ‘Brand of the Year - Acute category 2018’ for marketing excellence. This award is a testimony to Teamwork and accountability displayed by each member of the cross functional team associated with Tbact.
The company has been recognised as one of the 100 Best Companies for Women by Working Mother and AVTAR. The award was received by members of the Women's Leadership Board.
GSK topped the Access to Medicine Index (ATMI) for the sixth time in a row. ATMI is an independent measure of the top 20 pharmaceutical companies’ efforts to improve access to healthcare in developing countries.
GSK's Corporate Communication and Government Affairs team was recognised by Reputation Today as the 30 Top Corporate Communication Teams in India.
The company has been recognised as one of the 100 Best Companies for Women by Working Mother and AVTAR for the second time in a row. This is an important milestone in its inclusion and diversity journey.
GSK has been recognised as the 'Best Workplaces for Women' by Great Places To Work in India. This award celebrates the efforts of the company's Women's Leadership Initiative towards creating an inclusive work environment.

2019:

GSK won the 2019 D&I in India Best Practices Awards in the 'Advancement of Women' category by Community Business.
GSK won the award for the 'Best Sales and Operations Planning Practice in Pharma' 2019.
T-Bact won 'Brand of the Year' award in the acute category for the second consecutive year in 2019 at the 6th AWACS Awards for marketing excellence.

2020:

GSK was recognised as India’s Best Workplaces for Women 2020 by Great Places to Work.
GSK was recognised as 100 Best Companies for Women in India 2020 by Working Mother and AVTAR.

2021:

GSK recognised as one of the 100 Best Companies for Women in India 2021 by Working Mother and AVTAR.
GSK Pharma India recognised as one of India’s Best Workplaces in Health & Wellness 2021 by Great Place to Work.

2022:

GSK India conferred the First Runner-up title at the ASSOCHAM (Associated Chambers of Commerce and Industry of India) 3rd Diversity & Inclusion Excellence Awards - 2022 in the Best Employer for Women category.
GSK India wins 'Best Sales Onboarding/ Induction Programme' award at the 2nd Annual Sales L&D Summit and Awards 2022.
GSK India has been recognised amongst 'India's Best Workplaces in Health & Wellness 2022' by the Great Places to Work Institute.

2023:

Economic Times names GSK India as one of the 'Best Organisations for Women 2023'.
GSK India recognised as one of the 'Most Attractive Employers' in 2023 by Universum.
GSK India conferred the Bronze award in the ‘CSR Women and Child health’ category at the 7th edition of the CSR Health Impact award 2023.
Recognised as 'Progressive Places to Work 2023' by Economic Times (ET) Now.
Recognised as 'Top 24 Employers of the Future 2023' by Fortune India and Work Universe.

2024:

GSK India has been recognized as the 'Best Organisations for Women 2024' by ET Now.
Avtar & Seramount Best Companies for Women in India (BCWI) 2024.

2025:

GSK inducted in the BCWI Hall of Fame for featuring in the list for 5 or more years.
GSK recognized as a winner in the 2025 Avtar & Seramount BCWI study.

2026:

GlaxoSmithKline Pharmaceuticals Ltd. Wins ‘In-House Legal Team of the Year’ at the 6th Annual Corporate Legal Counsel Summit & Awards 2026.

Milestones

1924: Glaxo comes to India as H J Foster and Co.
1947: Secondary manufacturing of pharmaceuticals begins at Glaxo’s Worli plant.
1956: Primary production of vaccines begins at Worli plant.
1968: Glaxo is registered as Limited company.
1972: Scientists at Beecham Research laboratories discover Amoxycillin and launch Amoxil, which eventually becomes a widely used antibiotic.
1981: Augmentin was launched by Beecham to combat a wide range of bacterial infections in children and adults and the antiviral Zovirax was launched by Wellcome for harpes infections.
1983: Glaxo’s Nashik factory commissioned.
1999: Glaxo India completes 75 years in India.
2001: Legal merger of Glaxo India Limited and SmithKline Beecham Pharmaceuticals (India) Limited to form GlaxoSmithKline Pharmaceuticals Limited.
2015: GSK acquired Novartis vaccines business (excluding influenza vaccines).
2016: Launched Priorix- Tetra.
2018: Launched Infanrix Hexa.
2019: Launched Menveo (Quadrivalent Meningococcal Conjugate Vaccine).
2019: The company has launched Spectrum, an employee resource group for raising awareness on LGBT+ among the employees.
2019: Launched a development programme GSK WeLeAP - GSK Women Leadership Action Programme - to develop high potential mid-level women talent.
2021: GSK, PATH and Bharat Biotech sign product transfer agreement to help ensure long-term supply of ground-breaking malaria vaccine.
2022: GSK launches once daily, single inhaler-triple therapy for COPD patients for the first time in India.
2023: GSK launches Shingrix in India- A vaccine for the prevention of shingles in adults aged 50 years and above.
2023: Amitabh Bachchan partners with GSK for shingles awareness and prevention.
2024: GlaxoSmithKline Pharmaceuticals Limited crosses Rs 1000 crore in Revenue from Operations.
2025: GSK forays into Oncology in India with Jemperli and Zejula, Bringing Precision Therapies for Gynaecological Cancers.

Glaxosmithkline Pharmaceuticals Ltd (GLAXO)

Glaxosmithkline Pharmaceuticals Ltd (GLAXO)

Glaxosmithkline Pharmaceuticals stock performance